| Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy (NCT07341191) | Canadian Cancer Trials Group | 2026-08-31 |
| Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated With Immuno-Oncotherapeutics (NCT06630273) | Canadian Cancer Trials Group | 2026-07-31 |
| GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours (NCT07297667) | Canadian Cancer Trials Group | 2026-07-30 |
| Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials (NCT07390435) | Canadian Cancer Trials Group | 2026-05-15 |
| Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma (NCT07152821) | Canadian Cancer Trials Group | 2026-03-31 |
| Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer (NCT06686771) | Canadian Cancer Trials Group | 2025-12-16 |
| STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma (NCT06880523) | Canadian Cancer Trials Group | 2025-10-21 |
| Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (NCT06592924) | Canadian Cancer Trials Group | 2025-05-28 |
| Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer (NCT06641791) | Canadian Cancer Trials Group | 2025-04-07 |
| LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma (NCT06623461) | Canadian Cancer Trials Group | 2025-04-07 |
| Smartphone App-Based Mindfulness Intervention for French and English Speaker Cancer Survivors (NCT05470010) | Canadian Cancer Trials Group | 2025-03-07 |
| Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases (NCT06391242) | Canadian Cancer Trials Group | 2025-03-07 |
| Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes (NCT06439225) | Canadian Cancer Trials Group | 2024-12-30 |
| STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision (NCT06358469) | Canadian Cancer Trials Group | 2024-12-10 |
| Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer (NCT06205485) | Canadian Cancer Trials Group | 2024-06-26 |
| Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment (NCT06235697) | Canadian Cancer Trials Group | 2024-04-25 |
| Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma (NCT06043427) | Canadian Cancer Trials Group | 2024-04-16 |
| Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma (NCT06182774) | Canadian Cancer Trials Group | 2024-04-10 |
| Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma (NCT05998642) | Canadian Cancer Trials Group | 2024-02-13 |
| Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer (NCT05714891) | Canadian Cancer Trials Group | 2023-09-15 |
| Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer (NCT05601440) | Canadian Cancer Trials Group | 2023-06-13 |
| RP-6306 in Patients With Advanced Cancer (NCT05605509) | Canadian Cancer Trials Group | 2023-05-24 |
| PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (NCT05743777) | Canadian Cancer Trials Group | 2023-05-12 |
| Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: (NCT05371808) | Canadian Cancer Trials Group | 2023-01-27 |
| Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER (NCT05640999) | Canadian Cancer Trials Group | 2022-12-19 |
| Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma (NCT05180097) | Canadian Cancer Trials Group | 2022-11-01 |
| Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (NCT04918186) | Canadian Cancer Trials Group | 2022-05-03 |
| Emotion and Symptom-Focused Engagement Trial for Individuals With Acute Leukemia (NCT04224974) | Canadian Cancer Trials Group | 2022-01-06 |
| 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer (NCT04663997) | Canadian Cancer Trials Group | 2021-08-11 |
| Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (NCT04650581) | Canadian Cancer Trials Group | 2021-01-27 |
| Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (NCT04442048) | Canadian Cancer Trials Group | 2020-10-01 |
| Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma (NCT04161248) | Canadian Cancer Trials Group | 2020-09-02 |
| CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer (NCT04176848) | Canadian Cancer Trials Group | 2020-08-10 |
| Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer (NCT04093167) | Canadian Cancer Trials Group | 2020-05-26 |
| A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies (NCT03847649) | Canadian Cancer Trials Group | 2020-03-09 |
| Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer (NCT03784755) | Canadian Cancer Trials Group | 2019-11-15 |
| Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer (NCT03768570) | Canadian Cancer Trials Group | 2019-10-25 |
| De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma (NCT03822897) | Canadian Cancer Trials Group | 2019-06-28 |
| Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) (NCT03461952) | Canadian Cancer Trials Group | 2019-03-11 |
| CFI-400945 in Patients With Advanced/Metastatic Breast Cancer (NCT03624543) | Canadian Cancer Trials Group | 2019-02-14 |
| CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer (NCT03568422) | Canadian Cancer Trials Group | 2019-02-05 |
| Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases (NCT03550391) | Canadian Cancer Trials Group | 2018-11-22 |
| Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer (NCT03488693) | Canadian Cancer Trials Group | 2018-10-16 |
| Prostate Cancer Biomarker Enrichment and Treatment Selection (NCT03385655) | Canadian Cancer Trials Group | 2018-08-01 |
| ASA in Prevention of Ovarian Cancer (STICs and STONEs) (NCT03480776) | Canadian Cancer Trials Group | 2018-07-24 |
| NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer (NCT03259035) | Canadian Cancer Trials Group | 2018-06-29 |
| Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC (NCT03410615) | Canadian Cancer Trials Group | 2018-05-28 |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (NCT03297606) | Canadian Cancer Trials Group | 2018-03-23 |
| Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases (NCT02974803) | Canadian Cancer Trials Group | 2018-02-09 |